Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

The drug could also have a unique selling point in this indication as results from the phase 3 trial came from Libtayo monotherapy ... who cannot tolerate the side effects.